PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_7860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_6860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_5860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_4860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_2860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening Apr 05, 2023

Show notes

Go online to PeerView.com/WQZ_1860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT Apr 04, 2023

Show notes

Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT therapy based on disease risk factors; use of JAK inhibitor in non-HCT settings; practical dosing and safety management considerations; and the emergence of novel targeted and combinatorial strategies in the MF setting. Watch this informative update on personalized care for patients with MF! Upon completion of this activity, participants should be better able to: Discuss patient- and disease-related features of MF that inform prognosis and guide the selection of JAK inhibitors, other targeted strategies, and HCT; Summarize efficacy and safety data surrounding the use of JAK inhibitors, novel targeted strategies, and innovative combination regimens in MF across the therapeutic continuum; and Develop treatment plans that incorporate JAK inhibitors and other novel therapies to manage MF in HCT and non-HCT settings

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care Mar 29, 2023

Show notes

Go online to PeerView.com/WCP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options. Upon completion of this activity, participants should be better able to: Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis; Identify patients with psoriasis who are most likely to benefit from novel oral treatments; Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines; and Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis.

James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes Mar 28, 2023

Show notes

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment Mar 28, 2023

Show notes

Go online to PeerView.com/FTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed. There is also an increasing need for new ways to measure response to immunotherapies as they transition to early-stage, curative-intent settings in different solid tumors. Pathologic response assessment has emerged as a promising approach for evaluating the impact of neoadjuvant immunotherapy in lung, breast, and other cancers. However, limited guidance has been available on how to define and measure pathologic response, and report and apply assessment results. In this educational activity, experts provide up-to-date instruction and practical guidance on how to improve predictive immunotherapy biomarker testing and establish best practices for pathologic response assessment after neoadjuvant immunotherapy based on the evolving evidence, new guidelines, and illustrative case scenarios. Upon completion of this activity, participants should be better able to: Describe the recommendations and practical considerations for cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings; Perform appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings; and Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, pulmonologists, surgeons, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making across different tumors and treatment settings

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected